Current opinion in essential thrombocythemia: Pathogenesis, diagnosis, and management

Blood Reviews

Volumn 15, Issue 3, 2001, Pages 121-131

  Tefferi, A ^a   Murphy, S ^b  

^a MAYO CLINIC   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; HYDROXYUREA; INTERLEUKIN 6; PHOSPHORUS 32; PIPOBROMAN; THROMBOPOIETIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BLEEDING; FETUS WASTAGE; HUMAN; MALIGNANT TRANSFORMATION; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034778313     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0158     Document Type: Article

References (166)

1. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count
2. Chronic myeloid disorders: Classification and treatment overview
3. Clonal development of myeloproliferative disorders: Clues to hematopoietic differentiation and multistep pathogenesis of cancer
4. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia
5. Essential thrombocythemia: Another 'heterogeneous disease' better understood?
6. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
7. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value
8. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: Immunoperoxidase staining patterns and clinical correlates
9. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
10. Clonal analysis of haemopoietic cells in essential thrombocythaemia
11. Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets
12. Evaluation of clonality in myeloid stem-cell disorders
13. Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction
14. Clonality markers in polycythaemia and primary thrombocythaemia
15. Clonal haemopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes
16. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age
17. Clonality analysis using X-chromosome inactivation patterns by HUMARA-PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan
18. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (HUMARA). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis
19. Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia
20. Patients with essential thrombocytemia and clonal hemopoiesis detected by X-inactivation pattern are at high risk for thrombotic complication
21. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis
22. Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels
23. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia
24. Study of the thrombopoietin receptor in essential thrombocythemia
25. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene
26. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
27. Hereditary thrombocythaemia in a Japanese family is caused by anovel point mutation in the thrombopoietin gene
28. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF
29. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L
30. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3
31. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia
32. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia
33. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets
34. Human platelets as a model for the binding and degradation of thrombopoietin
35. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacokinetics
36. 1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity
37. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells
38. Blood thrombopoietin, IL-6 and IL-I 1 levels in patients with agnogenic myeloid metaplasia
39. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes
40. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
41. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis
42. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera
43. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
44. 9/L
45. Occurrence, etiology, and clinical significance of extreme thrombocytosis: A study of 280 cases
46. Platelet millionaires
47. Deep venous thrombosis and postsplenectomy thrombocytosis
48. Thrombocytosis in children at one medical center of southern Taiwan
49. Etiology and incidence of thrombotic and hemorrhagic disorders in Thai patients with extreme thrombocytosis
50. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution
51. Platelet parameters and aggregation in essential and reactive thrombocytosis
52. Platelet distribution width for differential diagnosis of thrombocytosis
53. Template bleeding time and clinical hemorrhage in myeloproliferative disease
54. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests
55. Abnormal platelet function in myeloproliferative disorders
56. Qualitative platelet defects in chronic myeloproliferative disorders: Evidence for reduced ATP secretion
57. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications
58. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders
59. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency
60. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis
61. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis
62. Primary thrombocythaemia: A composite approach to diagnosis
63. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis
64. Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis
65. Thrombopoietin levels in patients with primary and reactive thrombocytosis
66. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia
67. Clinical correlates of megakaryocyte C-Mpl expression in essential thrombocythaemia: A clinicopathologic study of 169 patients
68. Bone marrow and peripheral blood findings in patients with extreme thrombocytosis. A report of 63 cases
69. Prognostic significance of bone marrow biopsy in essential thrombocythemia
70. Megakaryocytic colony formation (CFU-Meg) in essential thrombocythemia: Quantitative and qualitative abnormalties of bone marrow CFU-Meg
71. Diagnosing polycythemia vera: A paradigm shift
72. Normal ranges for packed cell volume and hemoglobin concentration in adults: Relevance to 'apparent polycythemia'
73. Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia
74. Endogenous erythroid and megakaryocytic colony formation in serum-free, cytokine-free collagen gels
75. Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia
76. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera
77. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome
78. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study
79. Thrombocytosis with sideroblastic erythropoiesis: A mixed myeloproliferative myelodysplastic syndrome
80. 5q-syndrome presenting as essential thrombocythemia: Myelodysplastic syndrome or chronic myeloproliferative disorders?
81. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry, and immunostaining from bone marrow biopsies
82. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
83. Morphology and classification of the myelodysplastic syndromes and their pathologic variants
84. Myelofibrosis with myeloid metaplasia
85. A long-term retrospective study of young women with essential thrombocythemia
86. Clinical course of essential thrombocythemia in 147 cases
87. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients
88. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia
89. Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients
90. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
91. No treatment for low-risk thrombocythaemia: Results from a prospective study
92. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients
93. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors
94. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
95. The use of aspirin in polycythaemia vera and primary thrombocythaemia
96. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
97. Acquired von Willebrand's disease in the myeloproliferative syndrome
98. Abnormalities of von Willenbrand factor in myeloproliferative disease: A relationship with bleeding diathesis
99. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma
100. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
101. Long-term use of anagrelide in young patients with essential thrombocythemia
102. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
103. Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon
104. Essential thrombocythemias. Clinical evolutionary and biological data
105. Anagrelide a new drug for treating thrombocytosis
106. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
107. Therapy with anagrelide in patients affected by essential thrombocythemia: Preliminary results
108. Treatment of essential thrombocythemia with anagrelide
109. Treatment of children with anagrelide for thrombocythemia
110. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia
111. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: Treatment experience in 48 patients in Germany
112. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications
113. Pipobroman therapy of essential thrombocythemia
114. Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients
115. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
116. Interferon alpha-2b in the long-term treatment of essential thrombocythemia
117. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia
118. Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia
119. The treatment of essential thrombocythaemia with radioactive phosphorus
120. Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available?
121. Outcome of 259 patients with primary proliferative polycythaemia (PPP) and idiopathic thrombocythaemia (IT) treated in a regional nuclear medicine department with phosphorus-32 - A 15 year review
122. Primary thrombocythaemia treated with busulphan
123. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia
124. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature
125. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea
126. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications
127. Acquired DNA mutations associated with in vivo hydroxyurea exposure
128. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
129. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation - A brief review of recent literature
130. Acute leukemia as a natural sequel to primary thrombocythemia
131. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment
132. Is hydroxyurea leukemogenic in essential thrombocythemia?
133. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
134. A single institutional experience with 43 pregnancies in essential thrombocythemia
135. Managing miscarriage
136. Essential thrombocythemia associated with recurrent abortions and fetal growth retardation
137. Successful pregnancies after recurrent abortions in mild essential thrombocythemia
138. Clinical manifestations of essential thrombocythemia in young adults
139. Thrombocythaemia and recurrent miscarriage
140. Different outcomes of pregnancy in women with essential thrombocytosis
141. Thrombocytosis and thrombocythaemia
142. Primary thrombocythemia and myocardial infarction in a 26-year-old woman with normal coronary arteriogram
143. Thrombocythaemia and recurrent late abortions: Normal outcome of pregnancies after antiaggregatory treatment. Case report
144. Idiopathic thrombocythemia and pregnancy: A report of a case
145. Primary thrombocythemia in pregnancy: A report of two cases
146. Idiopathic thrombocythemia and pregnancy; a case report
147. Essential thrombocythemia and complications of pregnancy
148. Primary thrombocythemia and pregnancy: Treatment and outcome in fifteen cases
149. Primary thrombocythaemia in pregnancy
150. Pregnancy in a young woman affected by essential thrombocythemia: A case report
151. Treatment of essential thrombocythemia during pregnancy: Antiabortive effect of interferon-alpha?
152. Essential thrombocythemia and pregnancy
153. Essential thrombocythemia during pregnancy
154. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia
155. Treatment of essential thrombocythemia during pregnancy with interferon-alpha
156. Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b
157. Alpha 2b-interferon therapy and pregnancy - Report of a case of essential thrombocythemia
158. Successful treatment of essential thrombocythemia with alpha interferon during pregnancy
159. Interferon-alpha 2a treatment in a pregnant woman with essential thrombocythemia
160. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a
161. Successful treatment of essential thrombocythaemia and recurrent abortion with alpha interferon
162. Platelet counts during pregnancy in essential thrombocythaemia treated with recombinant alpha-interferon
163. Childbearing age patients with essential thrombocythemia: Should they be placed on interferon?
164. Cytotoxic therapy and pregnancy
165. Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature
166. Clinical relevance of increased angiogenesis in essential thrombocythemia: A clinicopathologic study of 164 patients